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Bone marrow stromal cells
β-CateninOsteoporosis is one of the most prevalent skeletal system diseases; yet, its pathophysiological mechanisms re-
main elusive. Adipocytes accumulate remarkably in the bonemarrow of osteoporotic patients. The potential pro-
cesses and molecular mechanisms underlying adipogenesis in osteoporotic BMSCs have attracted signiﬁcant
attention as adipocytes and osteoblasts share common precursor cells. Some environmental factors inﬂuence
bone mass through epigenetic mechanisms; however, the role of epigenetic modiﬁcations in osteoporosis is
just beginning to be investigated, and there is still little data regarding their involvement. In the current study,
we investigated how epigeneticmodiﬁcations, including DNAmethylation and histonemodiﬁcations, lead to ad-
ipogenesis in the bone marrow during osteoporosis. A glucocorticoid-induced osteoporosis (GIO) mouse model
was established, and BMSCs were isolated from the bone marrow. Compared with normal BMSCs, osteoporotic
BMSCs had signiﬁcantly increased adipogenesis potential and decreased osteogenesis potential. In osteoporotic
BMSCs, PPARγ2 regulatory region DNA hypo-methylation, histone 3 and 4 hyper-acetylation and H3K9 hypo-
di-methylation were observed. These epigenetic modiﬁcations were involved not only in PPARγ2 expression
but also in osteoporotic BMSC adipogenic differentiation potential. We also found that Wnt/β-catenin signal
played an important role in the establishment andmaintenance of epigeneticmodiﬁcations at PPARγ2 promoter
in osteoporotic BMSCs. Finally, we inhibited adipogenesis and rescued osteogenesis of osteoporotic BMSCs by
modulating those epigenetic modiﬁcations. Our study provides a deeper insight into the pathophysiology of os-
teoporosis and identiﬁes PPARγ2 as a new target for osteoporosis therapy based on epigenetic mechanisms.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Osteoporosis is one of the most prevalent skeletal system diseases
and it is estimated to affect approximately 30% of women and 12% of
men over 50 years of age [18]. It is characterized by a decrease in boneand/or assembly of data, data
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attenuation of bone resistance and susceptibility to fracture. The patho-
genesis of the disease remains hitherto elusive, resulting in augmented
interest in basic and clinical research into themechanisms of osteoporo-
sis. Osteoporosis research initially focused on osteoclastic activity and
bone resorption processes, and then on osteoblastogenesis. More re-
cently, the differentiation potential of bone marrow stromal cells
(BMSCs) has become an area of intense interest [31].
BMSCs are multipotent as they able to differentiate into osteoblasts,
chondrocytes, adipocytes, and/or myocytes in vitro and following
in vivo implantation. As BMSCs are the shared precursor cells for osteo-
blasts and adipocytes, a reciprocal relationship between osteogenesis
and adipogenesis was previously postulated [25]. The fat theory for
osteoporosis postulates that the balance between these cell types is al-
ways impaired in bonemarrow from osteoporosis patients, with adipo-
genesis overwhelming osteogenesis to upset BMSC activity and the
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served in other physiological and pathological conditions, such as
aging, microgravity, immobilization, ovariectomy, diabetes, and gluco-
corticoid overdose [19,43]. The possibility of inhibiting BMSC adipogen-
esis opens new avenues for osteoporosis therapy; however, why BMSC
adipogenesis overwhelms osteogenesis in osteoporosis is currently
unknown.
Adipogenic differentiation is a complex process in which concerted
gene expression is precisely regulated by various adipogenic factors.
Among these factors, peroxisome proliferator-activated receptor γ
(PPARγ) and CCAAT/enhancer binding protein α (C/EBPα) play central
roles controlling many downstream adipogenic genes [6]. PPARγ, a
member of the hormone nuclear receptor superfamily, is the only
gene that is sufﬁcient to activate adipogenesis on its own [36,37].
PPARγ has two isoforms, PPARγ1 and PPARγ2; the latter has been
shown to be an adipocyte speciﬁc isoform and is more efﬁcient than
PPARγ1 in promoting adipocyte differentiation. PPARγ2 contains an ad-
ditional 30 amino acids at its N-terminus, that are not present in
PPARγ1, thus indicating that the transcription of each isoform is initiat-
ed at different start sites, and that it is differentially controlled. At the
onset of adipogenesis, C/EBPβ and C/EBPδ are quickly induced and sub-
sequently cooperate to activate PPARγ and C/EBPα expression to pro-
mote terminal adipogenesis [2,41]. Investigating PPARγ's role in
osteoporotic BMSC adipogenesis and how it ismodulated in osteoporot-
ic BMSCs could provide a deeper insight into osteoporosis pathophysiol-
ogy and highlight PPARγ as a target gene for osteoporosis prevention or
treatment.
There is no doubt of the importance of genetic factors in osteoporo-
sis. Some cases of osteoporosis resulting fromgenemutations have been
reported [23]; however, most cases involvemultiple genes, with no sin-
gle gene being responsible for the entire osteoporotic phenotype.
Osteoporosis is likely to involve complex gene–gene and gene–environ-
ment interactions. Some environmental inﬂuences that have been
shown to be important osteoporosis risk factors deserve muchmore at-
tention. Given the high stability of the genome, environmental factors
generally inﬂuence genome activity via mechanisms that do not alter
the DNA sequence. Some of thesemechanisms are deﬁned as epigenetic
mechanisms,which are inherited through generations and cell divisions
but do not alter the DNA sequence.
Epigenetic mechanisms include DNAmethylation, histonemodiﬁca-
tions and miRNAs [3]. DNAmethylation and histonemodiﬁcationmod-
ulate gene expression at the level of transcription while miRNAs exert
their effects at the post-transcriptional level. The most widely studied
epigenetic mark is DNA methylation, especially in oncogenesis. DNA
methylation is generally associated with transcriptional silencing.
Histonemodiﬁcations, includingmethylation, acetylation, phosphoryla-
tion, SUMOylation and ubiquitination, have also beenwidely investigat-
ed [10,30]. The effects of histone modiﬁcations are somewhat
complicated, as they depend not only on the type of histone modiﬁed
but also on the type and number of chemical groups that are added. In
general, histone modiﬁcations can be divided into two groups: those
that are associated with transcriptional activation (acetylation and
phosphorylation) and those that are associated with transcriptional
repression (methylation, ubiquitination and sumoylation) [27].
The involvement of epigenetic modiﬁcations in osteoporosis is just
beginning to be investigated, and data regarding its role in osteoporosis
is scarce. In the current study, a glucocorticoid-induced osteoporosis
(GIO) mouse model was established and BMSCs were isolated from
the bone marrow. Compared with normal BMSCs, osteoporotic BMSCs
had signiﬁcantly enhanced adipogenic differentiation potential as well
as PPARγ2 regulatory region DNA hypo-methylation, histone 3 and 4
hyper-acetylation, and H3K9 hypo-di-methylation. These epigenetic
modiﬁcations were involved not only in PPARγ2 expression but also
in the adipogenic differentiation potential of osteoporotic BMSCs. Final-
ly, we inhibited osteoporotic BMSC adipogenesis by modulating the
patterns of DNA methylation and histone modiﬁcations.2. Results
2.1. The attenuation of osteogenic potential and the enhancement of
adipogenic potential of osteoporotic BMSCs
In the current study, a GIO mouse model was established by intra-
peritoneal injection of Dex for 3 weeks as previously described [45,
46]. Saline-injectedmicewere used as controls and deﬁned as “normal”.
Micro-CT analysis showed reduced trabecular bone in the proximal tibia
(Fig. 1A), including lower bone volume, trabecular number and thick-
ness and higher trabecular space (Fig. 1B). BMSCs were isolated from
the bone marrow and cultured in vitro. Flow cytometry analysis re-
vealed that mesenchymal surface markers CD44, CD105 and CD90
were positive (Fig. 1C) and hematopoietic surface markers CD45 and
CD34 were negative in these cells (Fig. 1C). BMSCs are induced to oste-
ogenesis in vitro. At week 1, ALP staining analysis revealed that ALP ac-
tivation was weaker in osteoporotic BMSCs compared with normal
BMSCs (Fig. 1D). At week 3, Alizarin Red staining analysis revealed the
same pattern as ALP staining (Fig. 1D). The total RNA was extracted at
week 2 and used for quantitative RT-PCR analysis for several osteogenic
markers Runx2, ALP, BSP and OC. The qRT-PCR revealed the less signif-
icant BMP2-induced activation of Runx2, ALP, BSP and OC mRNA ex-
pression in osteoporotic BMSCs than normal BMSCs (Fig. 1E). These
results indicated that osteoporotic BMSCs had weaker osteogenic po-
tential compared with normal BMSCs.
Alternatively, BMSCs were induced to adipogenesis in vitro. At week
3, fat droplet generation was evaluated by Oil red O staining and quan-
tiﬁcation. As shown in Fig. 1F, more intracellular fat droplets were ob-
served in osteoporotic BMSCs compared with normal BMSCs. At both
weeks 0 and 1, total RNA was harvested for qRT-PCR using primers for
adipogenic markers PPARγ2, C/EBPα, and glut4. The qRT-PCR revealed
themore signiﬁcant activation of PPARγ2, C/EBPα, and glut4mRNA ex-
pression in osteoporotic BMSCs than normal BMSCs (Fig. 1G). Further,
upon in vitro adipogenic induction, the phosphorylation of PPARγ was
greater in osteoporotic BMSCs compared with normal BMSCs (Fig. S1).
Together, these lines of evidence suggested that osteoporotic BMSCs
had stronger adipogenic potential compared with normal BMSCs.
2.2. PPARγ2 promoter DNA hypomethylation in osteoporotic BMSCs
After observing the increased adipogenic potential of osteoporotic
BMSCs, we attempted to elucidate the underlying molecular mecha-
nisms. Our attention is focused on PPARγ2 in the current study. We an-
alyzed the mouse PPARγ2 promoter, which contains six CpG sites
(i.e., potential DNA methylation targets) around the transcription start
site (TSS) (Fig. 2A):−437 bp,−298 bp,−263 bp,−247 bp,−60 bp,
and +89 bp. The DNA sequence was shown in Fig. S2. The methylation
statuses of these six CpG sites were investigated in normal and osteopo-
rotic BMSCs with and without adipogenic induction. In the absence of
adipogenic induction, PPARγ2 promoter DNA hypomethylationwas ob-
served in osteoporotic BMSCs compared with normal BMSCs (Fig. 2B).
Similarly, osteoporotic BMSCs from GIO mice exhibited signiﬁcant
DNA hypomethylation upon 3-week adipogenic induction (Fig. 2B).
We also performed ChIP assays to measureMeCP2 binding. MeCP2 spe-
ciﬁcally binds to the DNA methylation sites in the PPARγ2 −446 to
−208 bppromoter region that contains four CpG sites in normal and os-
teoporotic BMSCswith andwithout adipogenic induction. IgG was used
as negative control. Without adipogenic induction, MeCP2 binding in
osteoporotic BMSCs was weaker than in normal BMSCs, although the
difference was not signiﬁcant (Fig. 2C). In contrast, upon adipogenic in-
duction, substantially weaker MeCP2 bindingwas observed in osteopo-
rotic BMSCs (Fig. 2C).
To further analyze PPARγ2 promoter methylation in osteoporotic
BMSCs, we investigated the timing of promoter methylation in BMSCs
in glucocorticoid-induced osteoporosis. BMSCs were isolated from
bone marrow at weeks 0–6 following Dex or saline injection. BMSC
Fig. 1. The attenuation of osteogenic potential and the enhancement of adipogenic potential of osteoporotic BMSCs. A glucocorticoid-induced osteoporosis (GIO) mouse model was
established by intraperitoneal injection of Dex (n=8) or saline (n=7) for 3weeks.Micro-CTwas employed to investigate the trabecular bone in the proximal tibia (A). BV/TV, trabecular
thickness, trabecular number and trabecular space were analyzed (B). BMSCs were isolated from the bone marrow, cultured in vitro and analyzed by ﬂow cytometry for mesenchymal
surface markers CD44, CD105 and CD90 and hematopoietic surface markers CD45 and CD34 (C). Then they were induced to undergo osteogenesis. Alkaline phosphatase (ALP) staining
and Alizarin red staining were performed at weeks 1 and 3, respectively (D). At week 2, the total RNAwas extracted and used for real-time PCR analysis with primers for Runx2, ALP, BSP
andOC (E).β-Actinwas used as an internal control. BMSCswere induced to adipogenesis. Atweek 3, fat droplet generationwas evaluated by Oid red O staining and quantiﬁcation (F). At 0
and 1weeks, total RNAwas harvested for quantitative RT-PCR using primers for PPARγ2, C/EBPα, and glut4 (G). HPRTwas used as an internal control. The results are expressed as the fold
change relative to normal BMSCs without induction. Data are shown as the mean ± SD. *: p b 0.05, **: p b 0.01. All the data were obtained from at least three independent experiments.
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HpyCH4IV and the level of demethylation was estimated by the cutting
efﬁciency (see Materials and methods section for details). We detected
a gradual demethylation of the PPARγ2 promoter following dexameth-
asone injection until reaching a plateau at weeks 5 and 6 (Fig. 2D). In
contrast, PPARγ2 promoter demethylation in normal BMSCs remained
relatively low from weeks 0 to 6, and no signiﬁcant changes were
observed (Fig. 2D).
2.3. PPARγ2 promoter DNA methylation regulates PPARγ2 expression
After observing PPARγ2 promoter hypomethylation in osteoporotic
BMSCs, we attempted to investigate its effects on PPARγ2 transcription.
Normal BMSCswere treatedwith aDNAmethyltransferase inhibitor, 5′-
aza (5 μM and 10 μM), to induce DNA hypomethylation. On day 2, totalRNA was recovered for quantitative RT-PCR using primers for PPARγ2.
This analysis showed that 5′-aza treatment led to an upregulation of
PPARγ2 transcription in a dose-dependent manner (Fig. 3A). When
BMSCs were treated with both 5′-aza and the adipogenesis induction
cocktail, 5′-aza could still cause anupregulation of PPARγ2 transcription
in a dose-dependent manner (Fig. 3A). MeCP2 binds to DNA methyla-
tion sites speciﬁcally to regulate target gene transcription. In the current
study, we used siRNA to silence MeCP2 expression in normal BMSCs
(Fig. 3B). PPARγ2 transcription was upregulated in response to MeCP2
knockdown (Fig. 3B). Similarly, a signiﬁcant upregulation in PPARγ2
transcription was also observed in response to MeCP2 knockdown
when BMSCs were induced to undergo adipogenesis (Fig. 3B).
Further, themouse PPARγ2 promoter (−602–+202 bp)was ampli-
ﬁed from genomic DNA by PCR and cloned into the pGL3-basic vector
(Fig. 3C). M.SssI was utilized to in vitromethylate the PPARγ2 promoter
Fig. 2. Osteoporotic BMSC PPARγ2 promoter DNA hypomethylation. Analysis of PPARγ2 promoter DNAmethylation and transcription factor binding sites revealed 6 CpG sites and a pu-
tative C/EBPβ binding site around the transcription start site (TSS;−258 to−245 bp) (A). Genomic DNA was isolated from normal and osteoporotic BMSCs with and without 3-week
adipogenic induction. TheDNAmethylation statuses of 6 PPARγ2 promoter CpG siteswere investigated (B). Open circles indicate unmethylated CpG sites and closed circles indicatemeth-
ylated CpG sites. ChIPwas performed tomeasureMeCP2 binding to the PPARγ2 promoter in normal and osteoporotic BMSCswith andwithout adipogenic induction (C). IgGwas used as a
negative control. The resultwas expressed as a percentage ofMeCP2 binding in input control. Genomic DNAwas isolated fromnormal and osteoporotic BMSCs at 0–6weeks following Dex
injection. The methylation statuses of the−437 bp,−298 bp and−247 bp CpG sites were determined by restriction endonuclease digestion and the fraction of promoter fragments in
which all three sites were unmethylated is depicted (D). Data are shown as themean± SD. *: p b 0.05, **: p b 0.01, GIO mouse vs. normalmouse. All the data were obtained from at least
three independent experiments.
Fig. 3.PPARγ2 promoterDNAmethylation regulates PPARγ2 expression.Normal BMSCswere treatedwith 5′-aza (5 and 10 μM). Total RNAwas harvested onday 2 for quantitative RT-PCR
using primers for PPARγ2 (A). The results are expressed as the fold change inmRNA abundance relative to “vehicle” culturewithout adipogenic induction. *: p b 0.05, **: p b 0.01, vs. “0 μM
adipogenic induction (−)” culture. siRNA-mediated knockdown of MeCP2 expression (B). A scrambled siRNA was used as a control. PPARγ2 mRNA expression was measured by quan-
titative RT-PCR (B). The results are expressed as the fold change inmRNA abundance relative to the “scramble” culturewithout adipogenic induction. *: p b 0.05, **: p b 0.01, vs. “scramble
adipogenic induction (−)” culture. The mouse PPARγ2 promoter region (−602–+202 bp) was cloned into the pGL3-Basic vector. M.SssIwas used to methylate CpG sites in vitro, and a
transient reporter assaywas performed in normal BMSCswith andwithout adipogenic induction (C). The results are expressed as the fold change in relative luciferase units (RLUs) relative
to the “empty reporter” in a medium culture. A transient reporter assay was performed in normal BMSCs with and without MeCP2 knockdown (D). The results are expressed as the fold
changes in RLU relative to the “empty reporter” in the scramble culture without adipogenic induction. The PPARγ2 core promoter (−203 –+202 bp) was inserted upstream of the lucif-
erase reporter, and ﬁve putative C/EBPβ binding sites were then inserted in tandem upstream of the PPARγ2 core promoter. A transient reporter assay was then performed in normal
BMSCs (E). The results are expressed as the fold change in RLU relative to the “empty reporter” culture. Data are shown as the mean ± SD. *: p b 0.05, **: p b 0.01. ChIP was performed
to measure C/EBPβ binding to the PPARγ2 promoter in normal and osteoporotic BMSCs with and without adipogenic induction (F). IgG was used as negative control. All the data were
obtained from at least three independent experiments.
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with and without adipogenic induction. As shown in Fig. 3C, in vitro
PPARγ2 promoter methylation resulted in a reduction in luciferase
activity. Furthermore, upon adipogenic induction, a reduction in lucifer-
ase activity was also observed in response to in vitro methylation
(Fig. 3C). A methylated PPARγ2 promoter-driven luciferase vector was
transfected into BMSCs with andwithoutMeCP2 knockdown. Transient
reporter assays indicated that the luciferase activity of the methylated
PPARγ2 promoter was increased in response to MeCP2 knockdown re-
gardless of adipogenic induction (Fig. 3D). Together, these lines of evi-
dence suggest that both DNA methylation and MeCP2 binding are
involved in BMSC PPARγ2 transcription.
We noticed a putative C/EBPβ binding site between−258 bp and
−245 bp of the PPARγ2 promoter; C/EBPβ is another key transcription
factor in adipogenesis (Fig. 2A). Several CpG sites surround this binding
site, and a CpG site lies within it (−247 bp); consequently, we were in-
terested in examining the role of C/EBPβ in osteoporotic BMSC expres-
sion of PPARγ2. We therefore inserted the PPARγ2 core promoter
(−203–+202 bp) upstream of the luciferase reporter, and ﬁve putative
C/EBPβ binding sites were introduced in tandem upstream of the
PPARγ2 core promoter (Fig. 3E). Transient reporter assays were then
performed in normal BMSCs. As shown in Fig. 3E, C/EBPβ binding
sites signiﬁcantly enhanced PPARγ2 core promoter luciferase activity.
C/EBPβ binding site-driven luciferase reporter activity was further en-
hanced in response to C/EBPβ overexpression (Fig. 3E).More importantly,
luciferase activity was reduced in response to in vitro methylation of the
C/EBPβ binding sites despite C/EBPβ overexpression (Fig. 3E).
Finally, we employed ChIP assays to study C/EBPβ binding to the
PPARγ2 promoter, and the results indicated that C/EBPβ could indeed
bind to that site in both normal and osteoporotic BMSCs (Fig. 3F). And re-
gardless of without or with adipogenic induction, C/EBPβ binding in os-
teoporotic BMSCs was stronger than in normal BMSCs (Fig. 3F). C/EBPβ
binding was enhanced when normal BMSCs were treated with 5′-aza
to induce DNAhypomethylation (Fig. 3F), suggesting a negative relation-
ship between DNA methylation and C/EBPβ binding to the PPARγ2
promoter.
2.4. PPARγ2 promoter histone modiﬁcations in osteoporotic BMSCs
PPARγ2 promoter histone modiﬁcations were also investigated in
osteoporotic BMSCs. We ﬁrst examined the global expression levels of
four core histone modiﬁcations, acetylated H3K9/K14 and H4K12, di-
methylated H3K9 and tri-methylated H3K27, in osteoporotic BMSCs at
0–3 weeks following Dex injection. Total H3 and H4were used as load-
ing controls. As shown in Fig. 4A, the global levels of all of the histone
modiﬁcations examinedwere stable during glucorticoid-induced osteo-
porosis, suggesting that these histone modiﬁcations are not globally af-
fected by osteoporosis.
Histones are important for gene regulation [46]. H3 and H4 tails are
heavily acetylated atmultiple sites, and these acetylation sites are gener-
ally linked to gene activation. In this study, we used ChIP assays to exam-
ine the roles of these two histone tails in the PPARγ2 regulatory regions
in normal and osteoporotic BMSCs; we selected H3K9/K14 and H4K12
acetylation to represent the acetylation of H3 and H4, respectively.
Three regions were examined: 2 kb and 1 kb upstream of the TSS, and
the promoter. Primer Chr.15 targets a silent region on mouse chromo-
some 15 that contains no known genes within 500 kb [38], while the
GAPDH primer targets the promoter region of the actively transcribed
GAPDH gene. Negative control experiments were performed in parallel
using IgG (Fig. S3). We observed signiﬁcant increases in H3K9/K14 and
H4K12 acetylationwithin the−2 kb,−1 kb and promoter regions in os-
teoporotic BMSCs compared with normal BMSCs (Fig. 4B and C).
Depending on the site and degree of histonemethylation, it can lead
to either gene activation or repression. Di-methylated H3K9 and tri-
methylated H3K27 are repressive marks although they function
through different mechanisms [20,44]. We examined the distributionof these two modiﬁcations in PPARγ2 in normal and osteoporotic
BMSCs using ChIP analysis. We observed a signiﬁcant decrease in H3K9
di-methylation in the−2 kb,−1 kb and promoter regions in osteopo-
rotic BMSCs compared with normal BMSCs (Fig. 4D). The PPARγ2 regu-
latory regions were devoid of H3K27 tri-methylation in both normal and
osteoporotic BMSCs, and the two cell types did not differ (Fig. 4E).
Notably, upon adipogenic induction, H3K9/K14 and H4K12 hyper-
acetylation andH3K9hypo-di-methylation in PPARγ2 regulatory region
were observed in osteoporotic BMSCs compared with normal BMSCs
(Fig. S4).
Finally, the binding of phosphorylated RNA polymerase II, a key com-
ponent of transcription machinery, to the mouse PPARγ2 promoter was
investigated using ChIP assays of normal and osteoporotic BMSCs. With-
out adipogenic induction, p-RNA polymerase II binding did not differ be-
tween these cell types (Fig. 4F); in contrast, when adipogenesis was
induced, stronger p-RNApolymerase II bindingwas observed in osteopo-
rotic BMSCs compared with normal BMSCs, suggesting that PPARγ2
transcriptional activity in osteoporotic BMSCs was stronger than in nor-
mal BMSCs (Fig. 4F).
2.5. Histone acetylation and H3K9 di-methylation regulate PPARγ2
expression in osteoporotic BMSCs
After observing the increase in histone acetylation and decrease in
H3K9 di-methylation in PPARγ2 regulatory regions in osteoporotic
BMSCs, we investigated whether these changes affected PPARγ2 ex-
pression.We ﬁrst studied PPARγ2 promoter HDAC1 (responsible for re-
moving histone acetyl groups), LSD1 (responsible for removing methyl
groups from H3K9) and SETDB1 (responsible for adding methyl groups
to H3K9) occupancy in normal and osteoporotic BMSCs. The ChIP assay
results indicated a decrease in HDAC1 and SETDB1occupancy and an in-
crease in LSD1 occupancy of the PPARγ2 promoter in osteoporotic
BMSCs comparedwith normal BMSCs, regardless of adipogenesis induc-
tion (Fig. 5A). These data were consistent with the increases in PPARγ2
H3K9/K14 and H4K12 acetylation and decrease in H3K9 di-methylation
in osteoporotic BMSCs (Fig. 4).
Normal BMSCs were treated with TSA, a histone deacetylase inhibi-
tor that causes histone hyper-acetylation, and total RNA was recovered
after two days for quantitative RT-PCR analysis of PPARγ2. This assay re-
vealed that TSA could promote PPARγ2 transcription (Fig. 5B); further-
more, when BMSCswere treatedwith TSA and the adipogenic induction
cocktail, TSA continued to promote PPARγ2 transcription (Fig. 5B).
siRNA-mediated silencing of LSD1 led to H3K9 hyper-methylation in
osteoporotic BMSCs (Fig. 5C). Without adipogenic induction, PPARγ2
transcription was unaltered in response to LSD1 knockdown (Fig. 5C);
in contrast, upon adipogenic induction, PPARγ2 transcription was sig-
niﬁcantly downregulated in response to LSD1 knockdown (Fig. 5C).
siRNA-mediated silencing of SETDB1 expression led to H3K9 hypo-
methylation in normal BMSCs (Fig. 5D). A signiﬁcant increase in
PPARγ2 transcription was observed in response to SETDB1 knockdown
regardless of adipogenic induction (Fig. 5D).
2.6. The involvement ofβ-catenin in the epigeneticmodiﬁcations at PPARγ2
promoter in osteoporotic BMSCs
We then attempted to elucidate themechanisms underlyingDNAhy-
pomethylation, histone hyperacetylation and H3K9 hypo-dimethylation
at PPARγ2promoter in osteoporotic BMSCs. Several reports have indicat-
ed that Dex prevents osteoblastogenesis partly by inhibiting theWnt/β-
catenin pathway [32,39,40]. To investigate whether the Wnt/β-catenin
pathway is involved in the epigeneticmodiﬁcations at PPARγ2 promoter
in osteoporotic BMSCs, we ﬁrst evaluated the protein expression of ac-
tive β-catenin in both normal and osteoporotic BMSCs. The Western
blot revealed the lower expression level of active β-catenin in osteopo-
rotic BMSCs comparedwith normal BMSCs (Fig. 6A). The qRT-PCR results
showed the signiﬁcant downregulation of Wnt target genes Axin2
Fig. 4.Histonemodiﬁcations in osteoporotic BMSC PPARγ2 regulatory regions. Histone samples were collected from osteoporotic BMSCs at 0–3weeks following Dex injection. Global his-
tonemodiﬁcation levelswere determined byWestern blot (A). Histones 3 and 4were used as loading controls. ChIP assayswere used to examine acetylatedH3K9/K14 (B), H4K12 (C), di-
methylatedH3K9 (D) and tri-methylatedH3K27 (E) occupancy in the PPARγ2−2 kb,−1 kb and promoter regions in normal and osteoporotic BMSCs. Chromosome 15 and GAPDHwere
used as negative and positive controls, respectively. Phosphorylated RNA polymerase II occupancy of the PPARγ2 promoter was measured in normal and osteoporotic BMSCs with and
without adipogenic induction (F). The results were normalized to the percentage of various histone modiﬁcations in the input control. Data are shown as the mean ± SD. *: p b 0.05,
GIO mouse vs. normal mouse. All the data were obtained from at least three independent experiments.
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normal BMSCs.
Next, we investigated the functional role of Wnt/β-catenin signal in
the establishment of DNAmethylation, histone acetylation andmethyla-
tion at PPARγ2 promoter. IWR-1was used to blockWnt/β-catenin signal
in osteoporotic BMSCs. At day 7, PPARγ2 promoter DNA hypomethyla-
tion (Fig. 6D), histone hyper-acetylation (Fig. 6E and F) and H3K9
hypo-dimethylation (Fig. 6G) were observed. Further, LiCl was used to
activate Wnt/β-catenin signal in osteoporotic BMSCs. At day 7, PPARγ2
promoter DNA hypermethylation (Fig. 6D), histone hypo-acetylation(Fig. 6E and F) and H3K9 hyper-dimethylation (Fig. 6G) were observed.
These results indicated that Wnt/β-catenin signal played an important
role in the epigenetic modiﬁcations at PPARγ2 promoter in osteoporotic
BMSCs.
2.7. The adipogenic differentiation potential of osteoporotic BMSCs is
inhibited by altering the patterns of epigenetic modiﬁcations
Following the observation of the PPARγ2 epigenetic modiﬁcation
changes in osteoporotic BMSCs and their effects on PPARγ2 expression,
Fig. 5. PPARγ2 promoter histone modiﬁcations regulate PPARγ2 expression. ChIP assays were performed to examine HDAC1, LSD1 and SETDB1 occupancy of the PPARγ2 promoter in
normal and osteoporotic BMSCs with and without adipogenic induction (A). IgG was used as negative control. Normal BMSCs were treated with TSA (100 nM), and total RNA was har-
vested onday 2 for quantitative RT-PCRusing primers for PPARγ2 (B). The results are expressed as the fold change inmRNAabundance relative to the “vehicle” culturewithout adipogenic
induction. siRNA-mediated knockdown of LSD1 (C) and SETDB1 (D) expression. Scramblewas used as control. Di-methylatedH3K9 PPARγ2 promoter occupancywasmeasuredby ChIP in
response to LSD1 and SETDB1 knockdown (C and D). PPARγ2 mRNA expression was measured by quantitative RT-PCR (C and D). The results are expressed as the fold change in mRNA
abundance relative to the “scramble” culture without adipogenic induction. Data are shown as the mean ± SD. *: p b 0.05. All the data were obtained from at least three independent
experiments.
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tion potential by altering the patterns of epigenetic modiﬁcations. We
overexpressed Dnmt3a to induce DNA hyper-methylation (Fig. 7A),
treated BMSCs with anacardic acid to induce H3K9/K14 (Fig. 7B) and
H4K12 (Fig. 7C) hypo-acetylation and overexpressed SETDB1 to induce
H3K9 hyper-di-methylation (Fig. 7D) at the PPARγ2 promoter in osteo-
porotic BMSCs that had been induced to undergo adipogenesis. At week
3, fat droplet generation was evaluated by Oil red O staining and quan-
tiﬁcation. As shown in Fig. 7E and F, Dnmt3a-overexpression, anacardic
acid treatment and SETDB1-overexpression signiﬁcantly inhibited fat
droplet generation in osteoporotic BMSCs. At week 1 after induction,
total RNA was harvested for quantitative RT-PCR using primers for
PPARγ2, C/EBPα, aP2 and glut4. The mRNA levels of these genes were
signiﬁcantly reduced in response to Dnmt3a-overexpression, anacardic
acid treatment and SETDB1-overexpression (Fig. 7G–J) when adipogen-
esis was induced in osteoporotic BMSCs.
It should be noted that besides PPARγ2, the changes of epigenetic
modiﬁcations in the regulatory regions of other genes, in response to
those epigenetic treatments described above, should not be excluded
due to their widespread effects. However, we are sure that PPARγ2 reg-
ulatory regions have remarkable sensitivity to those epigenetic treat-
ments, as shown in Fig. 7A–D, and Dnmt3a-overexpression, anacardic
acid treatment and SETDB1-overexpression could inhibit the adipogen-
esis of osteoporotic BMSCs through modulating the epigenetic status of
PPARγ2 at least in a large part, if not all.2.8. The osteogenic differentiation potential of osteoporotic BMSCs is
rescued by altering the patterns of epigenetic modiﬁcations
Finally, we attempted to modulate osteoporotic BMSCs osteogenic
differentiation potential by altering the patterns of epigenetic modiﬁca-
tions. We overexpressed Dnmt3a, treated BMSCs with anacardic acid
and overexpressed SETDB1 at the PPARγ2 promoter in osteoporotic
BMSCs that had been induced to undergo osteogenesis. At week 1, ALP
staining analysis revealed that anacardic acid treatment and SETDB1
overexpression could enhance BMP2-induced ALP activity but Dnmt3a
overexpression could not (Fig. 8A). At week 3, Alizarin Red staining
analysis revealed the same pattern as ALP staining (Fig. 8A). The total
RNA was extracted at week 2 and used for qRT-PCR analysis for
Runx2, ALP, BSP and OC. The results showed that anacardic acid and
SETDB1 overexpression enhanced BMP2-induced Runx2, ALP, BSP and
OC activation but Dnmt3a overexpression did not (Fig. 8B–E). These re-
sults indicated that the osteogenic differentiation potential of osteopo-
rotic BMSCs was rescued by anacardic acid and SETDB1 overexpression.3. Discussion
In the current study, a signiﬁcant enhancement of adipogenic differ-
entiation potential was observed for osteoporotic BMSCs compared
with normal BMSCs as measured by the expression of adipogenic
Fig. 6. The involvement of β-catenin in the epigenetic modiﬁcations at PPARγ2 promoter in osteoporotic BMSCs. BMSCs were isolated from the bone marrow of normal and osteoporotic
mice. Total proteins were harvested for Western blot using antibody against active β-catenin (A). β-Actin was used as loading control. Total RNA was extracted and used for real-time
PCR analysis with primers for Axin2 (B) and cyclin D1 (C). β-Actin was used as an internal control. The results were expressed as fold changes relative to “3d” culture of normal BMSCs.
IWR-1 (10−6 M) and LiCl (20 mM) were used to treat osteoporotic BMSCs. At day 7, genomic DNA was isolated and the DNA methylation statuses of 6 PPARγ2 promoter CpG sites were
investigated (D). Open circles indicate unmethylated CpG sites and closed circles indicate methylated CpG sites. ChIP assays were used to examine acetylated H3K9/K14 (E), H4K12
(F) and di-methylated H3K9 (G) occupancy in the PPARγ2−2 kb,−1 kb and promoter regions in osteoporotic BMSCs treated by IWR-1 and LiCl. Chromosome 15 and GAPDH were
used as negative and positive controls, respectively. The results were normalized to the percentage of various histone modiﬁcations in the input control. Data are shown as the mean ±
SD. *: p b 0.05, **: p b 0.01. GIO mouse vs. normal mouse, IWR-1 and LiCl vs. vehicle. All the data were obtained from at least three independent experiments.
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a number of previous reports. Previously, researchers identiﬁed a re-
markable accumulation of adipocytes in the bone marrow from osteo-
porotic patients compared with healthy elderly subjects, suggesting
that bone marrow adipogenesis was involved in osteoporosis patho-
physiology. Recently, in vivo proton magnetic resonance (1H MRS)
data indicated that increased bonemarrow adipogenesiswas associated
with reduced bone mineral density in patients [1,7,42]. In mice, a com-
plex fat phenotype of mixed brown and white adipose was observed in
the bonemarrow [13]. Additionalwork is required to determinewheth-
er the quality and quantity of marrow fat plays a functional role in oste-
oporotic deregulation of bone remodeling.
The potential biological functions and molecular mechanisms un-
derlying osteoporotic BMSC adipogenesis have attracted increasing at-
tention for multiple reasons. First, bone marrow adipocytes were ﬁrst
regarded as structural ﬁllers for the void within the bone marrow cavi-
ty; then, these cells were proposed to either store energy or exert bio-
logical effects on the adjacent tissues through cytokine production
[25] which either sustains or suppresses hematopoietic and osteogenic
processes [11,22,24,25]. Second, given that BMSCs are the shared pre-
cursor cells for osteoblasts and adipocytes, the osteoporotic phenotype
might be rescued by inducing osteoporotic bone marrow adipocyte
apoptosis, dedifferentiation to BMSCs, or even transdifferentiation to os-
teoblasts, which has potential to ameliorate low bone mass in osteopo-
rosis. The current study aimed to elucidate the molecular mechanisms
underlying osteoporotic BMSC adipogenesis.
The environment signiﬁcantly affects bonemass, even during gesta-
tion: the intra-uterine environmentwas shown to play an essential role
in fetal skeleton development not only at birth but also later in life. Body
weight, fat stores, physical activity and smoking are included as mater-
nal factors affecting neonatal bone mass. Similarly, vitamin D and calci-
um availability during pregnancy are also closely associated with fetal
skeletal development and childhood bone mass. Consequently, it
seems that epigenetic inﬂuences have a more important role in osteo-
porosis pathophysiology than genetic factors. The methylation status
of the glucocorticoid receptor (GR) and PPARα were reported to bealtered in response to maternal dietary restriction in rats, andmore im-
portantly, these changes persisted even after weaning and were trans-
mitted to the next generation [15–17]. An increased risk of several
metabolic and neurological disorders was reported in Dutch subjects
that had experienced famine in 1944, as well as the abnormal methyla-
tion status of various gene promoters, such as IGF2 and other genes, that
are related to tissue growth and metabolism [8,9]. The current study
provides direct evidence that the epigenetic landscape of the PPARγ2
regulatory region is altered in osteoporotic BMSCs, with changes, in-
cluding DNA hypo-methylation, histone hyper-acetylation and H3K9
hypo-di-methylation, as well as evidence regarding how these epige-
netic modiﬁcations regulate PPARγ2 expression and osteoporotic
BMSC adipogenic differentiation.
In the present study, CpG sites in the PPARγ2 regulatory regions
were de-methylated in osteoporotic BMSCs. One CpG site (−247 bp)
was included in the C/EBPβ binding site (−258 to−245 bp).We deter-
mined that MeCP2 was recruited to these CpG sites when they were
hyper-methylated in normal BMSCs, and C/EBPβ was recruited to its
binding site when the CpG sites were hypo-methylated in osteoporotic
BMSCs. The ChIP data indicated a negative relationship betweenMeCP2
and C/EBPβ binding to the PPARγ2 promoter (Figs. 2C and 3F). PPARγ2
expression is regulated by C/EBPβ during BMSC adipogenesis. C/EBPβ
and C/EBPδ exert their functions in adipocyte differentiation before
PPARγ and C/EBPα, and ectopic expression of C/EBPβ in non-
adipogenic ﬁbroblasts activates PPARγ and C/EBPα transcription [6].
Furthermore, PPARγ and C/EBPα expression was lost in mouse embry-
onic ﬁbroblasts (MEFs) obtained frommice lacking both C/EBPβ and C/
EBPδ, and these cells were unable to undergo adipogenic differentiation
[35]. MeCP2 speciﬁcally binds to methylated CpG sites within the ge-
nome and provides a platform for the binding of transcriptional activa-
tors and repressors. The current study provides insight into the
molecular mechanisms underlying how PPARγ2 promoter DNA meth-
ylation is linked to MeCP2 and C/EBPβ function to regulate PPARγ2
expression.
In this study, we observed the hyper-acetylation of H3 and H4 tails
within the PPARγ2 gene in osteoporotic BMSCs compared with normal
Fig. 7. Osteoporotic BMSC adipogenic differentiation potential is inhibited by alterations in the patterns of epigenetic modiﬁcations. Lentiviral overexpression of Dnmt3a and SETDB1 in
osteoporotic BMSCs. Osteoporotic BMSCs were treated with anacardic acid (4 μM). The DNAmethylation statuses of 6 CpG sites in the PPARγ2 promoter were investigated (A). Open cir-
cles indicate unmethylated CpG sites and closed circles indicate methylated CpG sites. ChIPwas performed tomeasure acetylated H3K9/K14 (B), acetylated H4K12 (C) and di-methylated
H3K9 (D) PPARγ2 promoter occupancy. The results were normalized to the percentage of various histone modiﬁcations in the input control. *: p b 0.05, **: p b 0.01. Osteoporotic BMSCs
overexpressing either Dnmt3a or SETDB1, or treatedwith anacardic acid were induced to undergo adipogenic differentiation. Atweek 3, fat droplet generationwas evaluated by Oil red O
staining (E) and quantiﬁcation (F). Total RNAwas harvested atweeks 0 and 1 for quantitative RT-PCRusing primers for PPARγ2 (G), C/EBPα (H), aP2 (I) and glut4 (J). HPRTwas used as an
internal control. The results are expressed as the fold change relative to the “medium” culture. Data are shownas themean±SD. *: p b 0.05, vs. adipogenic induction (−). All the datawere
obtained from at least three independent experiments.
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adipogenic differentiation potential. Our data are supported by previous
reports that PPARγ2 promoter H3K9 acetylation is signiﬁcantly upregu-
lated during adipogenesis [33] and is positively associatedwith PPARγ2
transcription. Our observations also suggest that HDAC1 is recruited to
the PPARγ2 promoter tomaintain the hypo-acetylation status of normal
BMSCs and is dislodged in osteoporotic BMSCs, leading to hyper-
acetylation (Fig. 5). TSA inhibition of HDACs led to PPARγ transcription-
al activation (Fig. 5). PPARγ2 gene expression and histone acetylation
are closely related. In addition to PPARγ2 promoter histone acetylation,
previous reports showed that the lysine (K)-acetyl-transferases (KATs)
p300/CBP34 and Tip60 (a MYST family member) [38], which catalyze
histone H3 and H4 acetylation, respectively, can bind PPARγ to form
heterodimers that activate PPARγ target gene expression. In contrast,
SIRT1, a major mammalian HDAC, binds to PPARγ and represses
PPARγ target gene expression.
In the current study, we observed PPARγ2 H3K9 hypo-di-methyla-
tion in osteoporotic BMSCs compared with normal BMSCs (Fig. 4),
which contributed to the enhancement of osteoporotic BMSC adipogenicdifferentiation potential. These data support earlier reports that H3K9 di-
methylation is a marker of inactive chromatin marker. When we used
siRNA to silence H3K9 demethylase LSD1, PPARγ2 transcription was re-
pressed, and knockdown of H3K9 methyltransferase SETDB1 produced
the opposite result by decreasing H3K9 dimethylation. Our data are con-
sistent with a previous report that the expression of several histone
demethylases and methyltransferases was increased during adipogene-
sis and that H3K4/K9 demethylase LSD1 knockdown resulted in a
marked reduction in 3T3-L1 preadipocyte differentiation. Our report
and their report differ in that they selected C/EBPα as target gene.
In the current study, we found that Wnt/β-catenin signaling played
an important role in the establishment and maintenance of epigenetic
modiﬁcations of PPARγ2 promoter in osteoporotic BMSCs. This result is
supported by a previous study. Li et al. found that the Wnt/β-catenin
pathway is involved in Dex-induced osteoporosis and C/EBPα pro-
moter methylation, and its activation by LiCl rescues the effect of Dex
on C/EBPα promoter methylation and osteoblast/adipocyte balance
[14]. Further, some previous studies indicated that non-canonical
Wnt signal induced osteoblastogenesis through PPARγ transrepression
Fig. 8. The osteogenic differentiation potential of osteoporotic BMSCs is rescued by altering the patterns of epigeneticmodiﬁcations. Osteoporotic BMSCs overexpressing either Dnmt3a or
SETDB1, or treatedwith anacardic acidwere induced to undergo osteogenic differentiation. Alkaline phosphatase (ALP) staining andAlizarin red stainingwere performed atweeks 1 and 3,
respectively (A). At week 2, the total RNA was extracted and used for real-time PCR analysis with primers for Runx2 (B), ALP (C), BSP (D) and OC (E). β-Actin was used as an internal
control. The results were expressed as fold changes relative to a “medium” culture. *: p b 0.05, **: p b 0.01. All the data were obtained from at least three independent experiments.
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catenin signal as potential target to treat osteoporosis.
In the current study, we attempted to modulate osteoporotic
BMSC potential for adipogenic differentiation by altering epigenetic
modiﬁcations using two methods: gene engineering and treatment
with exogenous inhibitors. Dnmt3a-overexpression caused DNA
hyper-methylation, anacardic acid treatment caused H3 and H4 tail
hypo-acetylation, and SETDB1-overexpression caused H3K9 hyper-di-
methylation of PPARγ2 in osteoporotic BMSCs. In response to these
treatments, osteoporotic BMSC adipogenic differentiation was signiﬁ-
cantly inhibited. Investigations into osteoporosis epigenetics may pro-
vide not only a deeper insight into osteoporosis pathophysiology but
also reveal speciﬁc genes as new targets for epigenetics-based osteopo-
rosis therapy. Some anti-methylation agents are already employed to
treat tumors [12,28], and perhaps these agents can be used in osteopo-
rosis; however, their widespread effects are some of the most signiﬁ-
cant detractions limiting their potential utility. Agents that can
speciﬁcally modulate the epigenetic modiﬁcations of certain genes in
a given pathway would be of much greater use. In the current study,
we obviously cannot exclude the widespread effects of Dnmt3a-
overexpression, anacardic acid treatment and SETDB1-overexpression.
However, we conﬁrmed that PPARγ2 regulatory regions have remark-
able sensitivity to those epigenetic treatments and their overall effects
on osteoporotic BMSCs were inhibiting adipogenic differentiation
through PPARγ2 at least in a large part, if not all.
In addition, the osteogenic differentiation potential of osteoporotic
BMSCs was investigated in response to Dnmt3a overexpression,
anacardic acid treatment and SETDB1 overexpression. We found that
Dnmt3a overexpression could not enhance the osteogenic differentia-
tion of osteoporotic BMSCs. In a recent study, Nishikawa K et al. identi-
ﬁed Dnmt3a as a transcription factor that couples these metabolic
changes toosteoclast differentiation. They found that SAM-mediated
DNAmethylation by Dnmt3a regulates osteoclastogenesis via epigenet-
ic repression of anti-osteoclastogenic genes [21]. Therefore, we specu-
late that Dnmt3a might regulate bone mass and homeostasis through
modulating osteoclastogenesis, but not osteoblastogenesis.
In the current study, we found that anacardic acid treatment and
SETDB1 overexpression were effective in the rescue of the osteogenicdifferentiation of osteoporotic BMSCs. There are rare reports to investi-
gate the role of anacardic acid in BMSC osteogenesis. To our knowledge,
the current study is the ﬁrst one to evaluate its effect on osteogenesis
and to conﬁrm that anacardic acid treatment could enhance osteogenic
differentiation potential of osteoporotic BMSCs. For SETDB1, previous
studies mainly focused its role in the transrepression of PPARγ and
the inhibition of adipogenesis [21]. Our current study paid attention to
osteogenesis and conﬁrmed that SETDB1 overexpression could rescue
the osteogenic differentiation potential of osteoporotic BMSCs. We be-
lieve that our study provides deeper insights into themechanisms of os-
teoporosis and stronger evidences that SETDB1 can be regarded as a
potential target to develop anti-osteoporosis drugs.
In summary, the results of the current study suggest that DNA is de-
methylated, H3 and H4 tails are acetylated, and H3K9 di-methylation is
reduced in PPARγ2 regulatory regions in osteoporotic BMSCs compared
with normal BMSCs. These epigenetic modiﬁcations lead to an active
chromatin structure that activates PPARγ2 transcription in response to
adipogenic induction. Consistent with this idea, osteoporotic BMSCs
showed enhanced potential for adipogenic differentiation in response
to PPARγ2 epigenetic modiﬁcations (Fig. 9).
4. Materials and methods
4.1. GIO mouse model
BALB/c mice (7 months old, approximately 25 g bodyweight) were
housed in the Shanghai Jiaotong University School of Medicine Animal
Facility under standard conditions. The mice were dosed once daily in-
traperitoneally with saline (n= 7) or dexamethasone (Dex) phosphate
(n = 8) (5 mg/kg; Sigma, St. Louis, MO, USA) for 3 weeks. Throughout
the dosing period, themicewereweighed to examine the effects of dos-
ing on body weight. The animals were then sacriﬁced with an intraper-
itoneally injected overdose of sodium pentobarbitone. The femurs were
removed by dissection for micro-computerized tomography (CT) anal-
ysis using ScancoMedical CT-40 instruments. Three dimensional analy-
ses were performed to determine bone volume (BV)/tissue volume
(TV), trabecular number (Tb. N), trabecular thickness (Tb. Th), and tra-
becular separation (Tb. Sp) at the distal femur. The treatment protocol
Fig. 9. Epigenetic modiﬁcations in the PPARγ2 regulatory region contribute to the enhancement of osteoporotic BMSC potential for adipogenic differentiation. The PPARγ2 regulatory re-
gion DNA was de-methylated, H3 and H4 tails were acetylated, and H3K9 di-methylation was reduced in osteoporotic BMSCs compared with normal BMSCs. These epigenetic modiﬁca-
tions led to an active chromatin structure that activated PPARγ2 transcription in response to adipogenic induction. Consequently, the adipogenic differentiation potential of osteoporotic
BMSCs was enhanced.
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Committee of Shanghai Jiaotong University School of Medicine.4.2. BMSC isolation, culture, treatment and adipogenic differentiation
Tibia and femur bones were stripped of muscle and placed in ice cold
PBS supplementedwith 2% fetal bovine serum (FBS, Gibco by Invitrogen,
Carlsbad, CA, USA). The epiphyseal ends were then removed and the
bones were centrifuged at 4000 g for 1 min in a microfuge tube. The
bone marrow cells were then suspended in ice cold PBS supplemented
with 2% FBS, passed through a 70 μm ﬁlter and counted with a
hemocytometer.
Filtered bonemarrow cellswere suspended in PBS containing 2% FBS
and 0.1 g/L phenol red and then enriched for lineage negative (Lin−)
cells using the SpinSep system (Stem Cell Technologies, Vancouver,
BC, Canada). The cells were incubatedwith a murine progenitor enrich-
ment cocktail (anti-CD5, anti-CD45R, anti-CD11b, anti-Gr-1, anti-
TER119, and anti-7/4; Stem Cell Technologies) on ice for 30 min,
washed, and then incubated with dense particles on ice for 20 min.
The cells were then layered on a density medium, centrifuged at
1200 g for 10 min, and the cells at the density medium/PBS interface
were collected, washed and counted.
Enriched bone marrow cells were seeded onto culture plates at a
density of 0.1 × 106 cells/cm2 in murine Mesencult media (Stem Cell
Technologies) containing 100 units/ml penicillin (Gibco), 100 μg/ml
streptomycin (Gibco) and 0.25 μg/ml amphotericin B (Gibco). The
media were changed after 48 h and adherent cells were maintained in
culture with twice weekly media changes.BMSCs were treated with 5 and 10 μM 5′-aza (Sigma), 100 nM
trichostatin A (TSA) (Sigma), 10−6 M Dex, 10−6 M IWR-1, 20 mM LiCl
and 4 μM anacardic acid (Sigma).
To induce osteogenic differentiation, BMSCswere treatedwith BMP-
2 (R&D Systems, Minneapolis, MN, USA) at ﬁnal concentrations of 150
ng/ml.
Adipogenic differentiation was induced as previously described [4];
brieﬂy, conﬂuent cells were fed with a complete adipogenic hormone
cocktail (DMEM supplemented with 10% FBS, 10 g/ml of insulin
(Sigma), 0.5 mM methylisobutylxanthine (MIX) (Sigma) and 1 μM
Dex (Sigma)). The start point of differentiation was referred to as day
0. On day 3, cells were fed with DMEM containing only insulin and
10% FBS. On day 6, complete adipogenic hormone cocktail was again
added.4.3. ALP staining and Alizarin Red staining
A previously described protocol was employed [45]. Cultured cells
were rinsed with a phosphate-buffered saline (PBS) three times and
ﬁxed with 4% paraformaldehyde for 10 min at 4 °C. The ﬁxed cells were
soaked in 0.1% naphthol AS-MX phosphate (Sigma) and 0.1% fast red vi-
olet LB salt (Sigma) in 56 mM 2-amino-2-methyl-1,3-propanediol
(Sigma) for 10min at room temperature, washedwith PBS, and then ob-
served under a digital camera.
Osteoblast maturation was examined by staining mineralized nod-
ules with Alizarin Red. After ﬁxation, the cells were washed with PBS
and soaked in 40 mM Alizarin Red (pH 4.2) for 30 min at 37 °C, then
washed with PBS and imaged.
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The cells were ﬁxed with 10% formalin for 1 h and then stained in
pre-warmed Oil red O solution for 1 h in a 60 °C water bath. The red-
stained lipid droplets were observed under a light microscope. To mea-
sure the quantiﬁcation of lipid accumulation, Oil red O was eluted by
adding 100% isopropanol and optical density was detected using a spec-
trophotometer at 520 nm.
4.5. Reverse transcription (RT)-PCR and real-time PCR
Total RNA was isolated from BMSCs using an RNeasy Mini Kit
(Qiagen, Valencia, CA, USA) according to the manufacturer's protocol.
For RT-PCR, single-stranded cDNA was reverse-transcribed from 1 μg
of total RNA using reverse transcriptase and an oligo-dT primer. PCR
was performed with 1 μl of cDNA using the following cycling parame-
ters: 30 cycles of 94 °C for 40 s, 60 °C for 40 s, and 72 °C for 40 s. The
PCR products were then analyzed by agarose gel electrophoresis. Quan-
titative PCR was performed using a 96-well-plate ABI Prism 7500 (Ap-
plied BioSystems, Foster City, CA, USA) and SYBR Green PCR Master
Mix (Takara Bio Inc., Otsu, Japan). Cycling conditions were as follows:
94 °C for 30 s followed by 40 cycles of 94 °C for 5 s and 60 °C for 34 s.
The comparative 2−ΔΔCt method was used to calculate the relative ex-
pression of each target gene. Glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) was used as an internal control for RT-PCR and
hypoxanthine guanine phosphoribosyl transferase (HPRT) was used as
an internal control for quantitative RT-PCR. Primer sequences used in
RT-PCR were listed in Table S1. Primer sequences used in quantitative
RT-PCR were used in Table S2.
4.6. Western blot
Histone preparations from BMSCs at different time points during
glucocorticoid-induced osteoporosis were prepared as previously de-
scribed [29]. Total proteins from BMSCs treated by Dex at different
time points were prepared. Equal amounts of proteins were resolved
by 15% SDS-PAGE, transferred onto PVDF membranes and probed
with antibodies recognizing non-phospho (active) β-catenin (Cell Sig-
naling Technology, Danvers, MA, USA), H3K9/K14 acetylation, H4K12
acetylation and H3K27 tri-methylation (Upstate, New York, NY, USA),
and H3K9 di-methylation, total H3 and total H4 (Abcam, Cambridge,
MA, USA).
4.7. DNA isolation and bisulﬁte sequencing PCR
Brieﬂy, 5 μg genomic DNAwas cut with EcoRI at 37 °C overnight and
then puriﬁed using NaOAc and absolute alcohol. The puriﬁed DNA was
denaturated for 15 min at 50 °C with 5.5 μl of 2 M NaOH. Two volumes
of 2% low-melting agarose were then added to the DNA solution and
agarose beads were formed by pipetting 10 μl aliquots of the DNA/aga-
rose mixture into cold mineral oil. Freshly prepared hydroxyquinone
(55 μl of 10 mM; Sigma) and sodium bisulﬁte (520 μl 40.5%, pH 5;
Sigma) were added, and the mixture was incubated under mineral oil
at 50 °C for 16 h. Modiﬁcation was completed by treatment with
NaOH (0.3 M ﬁnal concentration) for 10 min at room temperature.
PCR ampliﬁcations were performed in 20 μl reactions containing one
agarose/DNA bead and 2 units of rTaq polymerase (Takara). The primer
sequences were as follows: BS-PCR region 1, 5′-GATGTGTGATTAGGAG
TTTTAA-3′ (forward) and 5′-ACTATCTACTACTTTAACAAAA-3′ (reverse);
and BS-PCR region 2, 5′-ACACACCATTTTGTCACAACTG-3′ (forward) and
5′-AATAAACCAAAATAACATCTCT-3′ (reverse). The ampliﬁed PCR frag-
ments were gel-puriﬁed and cloned into the pMD19-T vector system
(Takara). Fifteen clones were sequenced per sample and the sense
strands were used to assess CpG site methylation.
For restriction enzyme digestion analysis, PCR products correspond-
ing to BS-PCR region 1, site−437 bp and site−247 bp were digestedwith HpyCH4IV (New England Biolabs, Ipswich, Massachusetts, USA)
and electrophoresed to separate the digested fragments (for region 1
fragments, at least one of −437 bp, and −247 bp was methylated)
and undigested fragments (for region 1 fragments, all of the four CpG
sites were unmethylated). The bisulﬁte reaction only converts
unmethylated cytosine residues to thymine andPCR fragments generat-
ed from unmethylated genomic DNA are resistant to HpyCH4IV diges-
tion. The relative levels of the digested and undigested fragments
were estimated following analysis of images of ethidium bromide
stained agarose gels using Quantity One™ software.4.8. Chromatin immunoprecipitation (ChIP)
Cells were cross-linked with 1% formaldehyde for 10 min at 37 °C
and crude nuclei were puriﬁed using a previously described protocol
[29]. The crude nuclei were sonicated to produce chromatin fragments
of approximately 500 bp. The antibodies used in the ChIP assay were
as follows: MeCP2, C/EBPβ, histone 3, H3K9 di-methylation, HDAC1,
and phospho-RNA polymerase II (Abcam); and H3K9/K14 acetylation,
H4K12 acetylation, and H3K27 tri-methylation (Upstate). Rabbit IgG
(Sigma) was included as a negative control. For each ChIP assay, 2–
5 μg of antibodieswas added and the sampleswere incubated overnight
at 4 °C. The ChIP and inputDNA sampleswere quantiﬁedby quantitative
PCR. For PPARγ2, primers targeting the regions 2 kb (−2 kb) and 1 kb
(−1 kb) upstream of the transcription start site (TSS) were used. Pro-
moter primers were designed to be within 500 bp upstream of the
TSS. Primer sequences used in ChIP-qPCR were listed in Table S3.4.9. Lentivirus
Lentiviral vectors containing the coding sequences of C/EBPβ, DNA
methyltransferase 3A (Dnmt3a), and SETDB1, and short interfering
(si)RNAs against MeCP2, LSD1 and SETDB1 were purchased from
Genecopoeia® (Rockville, MD, USA). Virus particles were generated as
previously described [5]. Brieﬂy, 1.3–1.5 × 106 293 T cells were plated
in a 10 cm dish and the transfection mixture was added directly to the
culture medium at 70–80% conﬂuence. Following transfection, the sam-
ples were incubated in a CO2 incubator at 37 °C for 48 h and the virus
particle-containing medium was then collected.4.10. Luciferase reporter assay
Cells were seeded into 24-well plates. All plasmids for transfection
were isolated using a Qiagen plasmid puriﬁcation kit (Qiagen). Tran-
sient transfections were performed using Lipofectamine 2000
(Invitrogen) according to the manufacturer's instruction; phRL-SV40
vector (Promega, Madison, WI, USA) was used as control for transfec-
tion efﬁciency. Forty-eight hours after transfection, both ﬁreﬂy and
Renilla luciferase activities were measured using a Dual-luciferase re-
porter assay system (Promega) and a Luminoskan TL plus Luminometer
(MTX Labsystems, Vienna, VA, USA) according to the manufacturer's
protocol. The relative luciferase units (RLUs), the ratios of ﬁreﬂy to
Renilla luciferase activities, were then obtained.4.11. In vitro methylation assay
M.SssI (New England Biolabs, Ipswich, MA, USA) (2 U/μg DNA) was
used to in vitromethylate CpG sites for 6 h at 37 °C and then inactivated
at 65 °C for 15min. TreatedDNA fragments and vectorswere ligated and
puriﬁed by phenol/chloroform extraction and ethanol precipitation. The
plasmid concentrations were determined bymeasuring the absorbance
at 260 nm.
2516 Y. Zhang et al. / Biochimica et Biophysica Acta 1852 (2015) 2504–25164.12. Statistical analysis
Statistical signiﬁcance was calculated using Student's t-test for two-
sample comparisons and one-way ANOVA for multiple comparisons in
SPSS 16.0 software. Tukey's test was applied to identify signiﬁcant dif-
ferences by ANOVA. Statistical signiﬁcance was determined using data
from at least three independent experiments, and p values of b0.05
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